IP Library Granted Patent US 9,322,039
Granted Patent B2
US 9,322,039 · App. 14/614,484 · Granted Apr 26, 2016

Compositions and methods for producing benzylisoquinoline alkaloids

Inventors: Christina D. Smolke (Menlo Park, CA); Kristy M. Hawkins (Oakland, CA)
Assignee: California Institute of Technology
C12P17/12C12N9/0022C12N9/0059C12N9/1007C12N9/1096C12N9/88C12N15/81C12P7/24C12P13/001C12P17/182
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,322,039
App. No.
14/614,484
Granted
Apr 26, 2016
Kind
B2
Abstract

The present invention relates to host cells that produce compounds that are characterized as benzylisoquinolines, as well as select precursors and intermediates thereof. The host cells comprise one, two or more heterologous coding sequences wherein each of the heterologous coding sequences encodes an enzyme involved in the metabolic pathway of a benzylisoquinoline, or its precursors or intermediates from a starting compound. The invention also relates to methods of producing the benzylisoquinoline, as well as select precursors and intermediates thereof by culturing the host cells under culture conditions that promote expression of the enzymes that produce the benzylisoquinoline or precursors or intermediates thereof.

Claims (23)

1. A method of preparing a metabolite of tyrosine that is a benzylisoquinoline alkaloid product, the method comprising:

a) culturing an engineered non-plant cell under conditions suitable for protein production, said engineered non-plant cell comprising three heterologous coding sequences, wherein the three heterologous coding sequences encode a first, second, and third enzyme, respectively, that are involved in a metabolic pathway that converts the tyrosine into the benzylisoquinoline alkaloid product, wherein the first, second, and third enzymes are operably connected along the metabolic pathway;

b) optionally adding tyrosine to the cell culture; and

c) recovering the benzylisoquinoline alkaloid product from the cell culture,

wherein the benzylisoquinoline alkaloid product is selected from the group consisting of a norcoclaurine, coclaurine, N-methylcoclaurine, 3′-hydroxy-N-methylcoclaurine, reticuline, 6-O-methyl-norlaudanosoline, 6-O-methyl-laudanosoline, laudanine, scoulerine, tetrahydrocolumbamine, canadine, salutaridine, salutaridinol, salutaridinol-7-O-acetate, and thebaine, and

wherein each of the first, second, and third enzymes involved in the metabolic pathway that produces the benzylisoquinoline alkaloid product is selected from the group consisting of L-tyrosine/dopa decarboxylase 1, L-tyrosine/dopa decarboxylase 2, Cytochrome P450 2D6, NADPH p450 reductase, Polyphenyloxidase, Tyrosine hydroxylase, GTPcyclohydrolase I, Monoamine oxidase A, Tyramine oxidase, Aromatic amino acid transaminase, Phenylpyruvate decarboxylase, Norcoclaurine synthase, Norcoclaurine 6-O-methyltransferase, Coclaurine-N-methyltransferase, Cytochrome P450 80B1, 4-O-methyltransferase, Berberine bridge enzyme, Reticuline 7-O-methyltransferase, Scoulerine 9-O-methyltransferase, Canadine synthase, Salutaridine reductase, Salutaridinol 7-O-acetyltransferase, Codeine reductase, and Berbamunine synthase.

2. The method of claim 1 , wherein the benzylisoquinoline alkaloid product is selected from the group consisting of norcoclaurine, coclaurine, N-methylcoclaurine, 3′-hydroxy-N-methylcoclaurine, reticuline, 6-O-methyl-laudanosoline, laudanine, scoulerine, tetrahydrocolumbamine, canadine, salutaridine, salutaridinol, salutaridinol-7-O-acetate, and thebaine.

3. The method of claim 1 , wherein the engineered non-plant cell is selected from the group consisting of microbial cells, insect cells, mammalian cells, bacterial cells, and yeast cells.

4. The method of claim 1 , wherein the engineered non-plant cell is cultured under in vitro conditions.

5. The method of claim 1 , wherein the engineered non-plant cell is cultured under in vivo conditions.

6. The method of claim 1 , wherein the engineered non-plant cell is cultured with a compound selected from the group consisting of tyrosine, tyramine, dopamine, 4-hydroxyphenylacetaldehyde, 4-hydroxyphenylpyruvate, norcoclaurine, coclaurine, N-methylcoclaurine, 3′-hydroxy-N-methylcoclaurine, reticuline, scoulerine, tetrahydrocolumbamine, laudanosoline, and norlaudanosoline.

7. The method of claim 1 , wherein the engineered non-plant cell is cultured with tyrosine, and wherein the recovered benzylisoquinoline alkaloid product is norcoclaurine.

8. The method of claim 1 , wherein the engineered non-plant cell comprises at least one of L-tyrosine/dopa decarboxylase 1, L-tyrosine/dopa decarboxylase 2, Norcoclaurine synthase, and Cytochrome P450 2D6.

9. The method of claim 1 , wherein the engineered non-plant cell is cultured with tyrosine, and wherein the recovered benzylisoquinoline alkaloid product is reticuline.

10. The method of claim 9 , wherein the engineered non-plant cell comprises at least one of L-tyrosine/dopa decarboxylase 1, L-tyrosine/dopa decarboxylase 2, Cytochrome P450 2D6, Monoamine oxidase A, Norcoclaurine synthase, Norcoclaurine 6-O-methyltransferase, Coclaurine-N-methyltransferase, Cytochrome P450 80B1, and 4-O-methyltransferase.

11. The method of claim 1 , wherein the engineered non-plant cell is cultured with tyrosine, wherein the engineered non-plant cell comprises at least one of L-tyrosine/dopa decarboxylase 1, L-tyrosine/dopa decarboxylase 2, Cytochrome P450 2D6, Monoamine oxidase A, Norcoclaurine synthase, Norcoclaurine 6-O-methyltransferase, Coclaurine-N-methyltransferase, Cytochrome P450 80B1, 4-O-methyltransferase, and Berberine bridge enzyme, and wherein the recovered benzylisoquinoline alkaloid product is scoulerine.

12. The method of claim 1 , wherein the engineered non-plant cell is cultured with norlaudanosoline, wherein the engineered non-plant cell comprises at least one of Norcoclaurine 6-O-methyltransferase, Coclaurine-N-methyltransferase, and 4-O-methyltransferase, and wherein the recovered benzylisoquinoline alkaloid product is selected from the group consisting of 6-O-methyl norlaudanosoline, 3′-hydroxy-N-methylcoclaurine, and reticuline.

13. The method of claim 1 , wherein the engineered non-plant cell is cultured with reticuline, wherein the engineered non-plant cell comprises at least one of Berberine bridge enzyme, Scoulerine 9-O-methyltransferase, and Canadine synthase, and wherein the recovered benzylisoquinoline alkaloid product is selected from the group consisting of scoulerine, tetrahydrocolumbamine, and canadine.

14. The method of claim 1 , wherein the engineered non-plant cell is cultured with reticuline, wherein the engineered non-plant cell comprises at least one of Cytochrome P450 2D6, Salutaridine reductase, and Salutaridinol 7-O-acetyltransferase, and wherein the recovered benzylisoquinoline alkaloid product is selected from the group consisting of salutaridine, salutaridinol, salutarinidol-7-O-acetate, and thebaine.

15. The method of claim 1 , wherein the engineered non-plant cell is cultured with norcoclaurine, wherein the engineered non-plant cell comprises at least one of Norcoclaurine 6-O-methyltransferase, Coclaurine-N-methyltransferase, Cytochrome P450 80B1, 4-O-methyltransferase, Berberine bridge enzyme, Scoulerine 9-O-methyltransferase, and Canadine synthase, and wherein the recovered benzylisoquinoline alkaloid product is selected from the group consisting of coclaurine, scoulerine, reticuline, 3′-hydroxy-N-methylcoclaurine, N-methylcoclaurine, tetrahydrocolumbamine, and canadine.

16. The method of claim 1 , wherein the engineered non-plant cell is cultured with norcoclaurine, wherein the engineered non-plant cell comprises at least one of Norcoclaurine 6-O-methyltransferase, Coclaurine-N-methyltransferase, Cytochrome P450 80B1, 4-O-methyltransferase, and Cytochrome P450 2D6, Salutaridine reductase, and Salutaridinol 7-O-acetyltransferase, and wherein the recovered benzylisoquinoline alkaloid product is thebaine.

17. The method of claim 1 , wherein the engineered non-plant cell is cultured with a second non-plant cell, wherein the second non-plant cell produces at least one of tyrosine, tyramine, dopamine, 4-hydroxyphenylacetaldehyde, 4-hydroxyphenylpyruvate, norcoclaurine, coclaurine, N-methylcoclaurine, 3′-hydroxy-N-methylcoclaurine, reticuline, scoulerine, tetrahydrocolumbamine, laudanosoline, and norlaudanosoline.

18. The method of claim 1 , wherein recovering the benzylisoquinoline alkaloid product from the cell culture comprises separating the benzylisoquinoline alkaloid product from cellular material to provide a product stream having the benzylisoquinoline alkaloid product.

Assignments (3)
SECURITY INTEREST Recorded Aug 29, 2025
From: ANTHEIA, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 072750/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2015
From: SMOLKE, CHRISTINA D.; HAWKINS, KRISTY
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 036764/0010 →
CONFIRMATORY LICENSE Recorded Jun 16, 2015
From: CALIFORNIA INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035920/0387 →
Continuity (4)
Division 11875814 · Oct 19, 2007
Provisional Application 60859149 · Nov 15, 2006
Provisional Application 60852954 · Oct 19, 2006
Related Publication 20150267233A1 · Sep 24, 2015